Care & Caregiving: Policy and payment models (Milestone 13.P)
Timeline Start - End2022 - 2025
Research Implementation AreaResearch on Care and Caregiver Support
Support a research program to address the impact of policy and payment models and insurance on persons living with dementia, their care partners, and health care systems as well as economic and organizational factors associated with uptake of health care services.
- Launch new research initiatives to support at least six new projects or activities focused on policy and payment models, health insurance, and/or the ability of people and families to pay for and access needed services and supports. Supported projects could include micro-simulation modeling, prediction modeling, or observational studies that address related topics, such as:
- The impact of health insurance access on health and wellbeing outcomes;
- How incentive structures can improve care for persons living with AD/ADRD;
- How policies of governments and other institutions influence access, use, and quality of health care;
- How policies and payment models impact what care is provided to whom; and/or
- Research to estimate or project the burden of AD/ADRD as well as integrating economic issues related to uptake of health care services.
Summary of Key Accomplishments
In May 2022, NIA supported a workshop hosted by the National Academies to explore how healthcare organizational change can improve care for persons living with AD/ADRD, including through sustainable care models and payment models. NIA also published a call for applications (RFA-AG-23-005) to identify whether cost-associated barriers to receiving new or repurposed drug treatments exist for minoritized persons living with AD/ADRD, and to evaluate the cost effectiveness and health equity implications of new therapeutics in these populations. This funding opportunity includes support for a development phase to engage stakeholders in the design of the study. Finally, a new concept was approved by NIA’s Council in May 2022 to address the lack of current, comprehensive, and transparent estimates of the full costs of dementia in the U.S.
The key accomplishments summary is current as of July 2022.
- RFA-AG-23-005: Health Equity and the Cost of Novel Treatments for Alzheimer’s Disease and Related Dementias (R61/R33 Clinical Trial Not Allowed)
Research Programs and Resources
- NASEM Meeting Mechanisms for Organizational Behavior Change to Address the Needs of People Living with Alzheimer's Disease and Related Dementias
- “Estimating the Monetary Costs of Dementia in the United States” - Approved concept from May 2022 https://www.nia.nih.gov/approved-concepts#estmc